Navigation Links
Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health

NEW YORK, Sept. 6 /PRNewswire/ -- Globally, approximately 418 million people are currently infected with hepatitis, and the unrecognized importance, danger, and costs of hepatitis in the 21st century cannot be understated or underestimated, according to Global Hepatitis Strategies, a new report by Kalorama Information.

Paradoxically, despite the obvious crisis, world governments are not taking the necessary steps to contain hepatitis. Yet the incidence and prevalence of hepatitis have begun to rise in certain parts of the global community, and even industrialized nations are lacking hepatitis control policies. Moreover, there is a greater crisis in hepatitis screening, diagnosis, and treatment emerging, particularly in those areas where HIV/AIDS is becoming more prevalent.

Kalorama Information estimates that the theoretical global market for all hepatitis testing products and therapeutics in 2006, assuming that aggressive screening were to be conducted, would be $3.3 trillion, with the western Pacific and southeast Asia showing the greatest need. However, the estimated realistic market potential for the various global regions for 2006, based on their currently reported hepatitis status and pricing structure, fell far short, reaching just $326 million.

"The strategic concept of hepatitis diagnosis and therapy is one of the most insufficiently recognized areas that the healthcare industry has ever seen," notes Kenneth. G. Krul, PhD, the report's author. "Governments, with the exception of a limited few, seem unable or unwilling to devise comprehensive hepatitis containment and prevention policies. In order to cope with the challenges and opportunities of hepatitis diagnostics and therapeutics, companies must think on a global basis, focusing on three points for the development of strategy: potential market, epidemiology (hepatitis patient trends), and technology."

Global Hepatitis Strategies focuses on the factors that influence policy aspects of hepatitis, the options presented, the factors associated with strategic market development of hepatitis diagnostics and therapeutics, and prospects for the future. The report analyzes strategic market effects of epidemiology, market potential and technology, trends in epidemiology, and social/political attitudes towards hepatitis. This report can be purchased directly from Kalorama Information by visiting: It is also available at

About Kalorama Information

Kalorama Information supplies the latest in independent market research on medical markets. For more information, contact Tom Ehart at 240-747-3014 or, or visit

SOURCE Kalorama Information
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Venture Investors early-stage fund grows to $115 million
2. Two convicted of selling $6 million in counterfeit Rockwell software on eBay
3. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
4. TomoTherapy raises $223 million in IPO
5. Fiserv reports $113.5 million in Q1 profit
6. Investors raise $25 million for biodiesel plant
7. Grow Milwaukee includes millions for tech funding
8. Mirus Bio, Pfizer enter multimillion-dollar research agreement
9. ConjuGon raises $3.3 million to fund clinical trials
10. TrafficCast secures $1 million line of credit
11. Make Mine a $Million shoots for May program
Post Your Comments:
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
Breaking Biology Technology:
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... 15, 2016 Transparency Market ... Recognition Market by Application Market - Global Industry Analysis Size ... to the report, the  global gesture recognition market ... and is estimated to grow at a CAGR ... 2024.  Increasing application of gesture recognition ...
Breaking Biology News(10 mins):